Long-term Study With Trazodone Once-a-Day

Overview

The aim of the present observational study is to assess the clinical response, functional impairment and quality of life in outpatients with Major Depressive Disorder who demonstrated an initial positive response to the acute treatment with Trazodone once-a-day monotherapy, for up to 24 weeks.

Full Title of Study: “Long-term Treatment With Trazodone Once-a-Day (TzOAD) in Patients With MDD: an Observational, Prospective Study”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: November 16, 2021

Detailed Description

This is an observational, prospective, single group, multicentre, international study. The present study is planned to assess, in a real-world setting, the long-term clinical response, functional impairment and quality of life in outpatients with Major Depressive Disorder who, according to the physician's judgment, have responded to the acute monotherapy (6 to 8 weeks of treatment) with Trazodone once-a-day and are eligible to continue Trazodone once-a-day monotherapy according to clinical practice.

Interventions

  • Drug: TraZODone Hydrochloride 300 MG
    • Oral administration of Trazodone once-a-day.

Arms, Groups and Cohorts

  • Trazodone once-a-day treated patients
    • Major Depressive Disorder outpatients who, following an initial positive response to the acute treatment with Trazodone once-a-day monotherapy, will be eligible to enter the continuation therapy and will be observed up to 24 weeks.

Clinical Trial Outcome Measures

Primary Measures

  • Clinical Global Impression-improvement scale responders percentage
    • Time Frame: 24(+4) weeks
    • The clinical response expressed as CGI-I responders’ percentage at 24 (+ 4) weeks.

Secondary Measures

  • Clinical Global Impression-improvement scale responders percentage
    • Time Frame: 12 (+ 3) weeks.
    • The clinical response expressed as CGI-I responders’ percentage at 12 (+ 3) weeks.
  • Clinical Global Impression-improvement scale responders percentage
    • Time Frame: 18 (+ 3) weeks
    • The clinical response expressed as CGI-I responders’ percentage at 18 (+ 3) weeks.
  • Sheehan Disability Scale score
    • Time Frame: 24-week period
    • The functional impairment evaluated over the 24-week period
  • EQ-5D-5L Quality of life scale
    • Time Frame: 24-week period
    • The quality of life evaluated over the 24-week period

Participating in This Clinical Trial

Inclusion Criteria

Male and female patients of any ethnic origin ≥18 years old at Baseline. Outpatients who meet the Diagnostic and Statistical Manual of Mental Disorders (DSM)-5 or the International Classification of Diseases (ICD)-10 criteria for MDD as their primary diagnosis and presenting with an episode of MDD. Patients judged as responders to the acute monotherapy with TzOAD after a minimum of 6 and a maximum of 8 weeks of treatment and who are eligible to continue the assigned monotherapy according to the physician's judgement. Patients legally capable of giving their written consent for participation in the study and for personal data processing and willing to comply with all study procedures. Exclusion Criteria:

Patients that meet any of the contraindications to the administration of TzOAD according to the approved SmPC. Patients with previous or current diagnosis of bipolar disorder, schizophrenia or other psychotic disorder, dysthymic or adjustment disorders, mental retardation, organic mental disorders or mental disorders due to a general medical condition. Patients with previous or current history of a clinically significant neurological disorder, or any neurodegenerative diseases that might compromise the participation in the study. Patients who are, according to the physician's judgement, at serious risk of suicide. Patients with substance abuse or dependence (except nicotine dependence), as defined by DSM-5. Patients participating in any pharmacological or non-pharmacological interventional study.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Aziende Chimiche Riunite Angelini Francesco S.p.A
  • Provider of Information About this Clinical Study
    • Sponsor

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.